Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of MYMD-1 in Healthy Adults
NCT05077865Phase 1Completed
- Sponsor
- TNF Pharmaceuticals, Inc.
- Start
- Apr 2021
- Primary completion
- Aug 2021
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of isomyosamine in Hashimoto thyroiditis (8 cohorts), sponsored by TNF Pharmaceuticals, Inc. Primary endpoints: Adverse Events up to 16 days, Changes in Clinical Laboratory Values (Chemistry, Hematology, Coagulation, Urinalysis) at Day 8 and 3 more. Started Apr 2021; status: completed.
02
Drugs
isomyosamine
03
Conditions
Hashimoto thyroiditis
Beyond the preview
Go deeper on NCT05077865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05077865.